These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 28669463

  • 1. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
    Trautmann ME, Van Gaal L, Han J, Hardy E.
    J Diabetes Complications; 2017 Sep; 31(9):1415-1422. PubMed ID: 28669463
    [Abstract] [Full Text] [Related]

  • 2. Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
    Busch RS, Ruggles J, Han J, Hardy E.
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29044860
    [Abstract] [Full Text] [Related]

  • 3. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
    Trautmann ME, Han J, Ruggles J.
    Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
    Owens DR, Traylor L, Dain MP, Landgraf W.
    Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of once-weekly insulin versus once-daily insulin in patients with type 1 and type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials.
    Xue M, Shen P, Tang J, Deng X, Dai Z.
    Front Endocrinol (Lausanne); 2024 Nov; 15():1459127. PubMed ID: 39629047
    [Abstract] [Full Text] [Related]

  • 6. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
    Wysham C, Bajaj HS, Del Prato S, Franco DR, Kiyosue A, Dahl D, Zhou C, Carr MC, Case M, Firmino Gonçalves L, QWINT-2 Investigators.
    N Engl J Med; 2024 Dec 12; 391(23):2201-2211. PubMed ID: 39254740
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis.
    Gourdy P, Bonadonna RC, Mauricio D, Müller-Wieland D, Mauquoi C, Vera C, Bonnemaire M, Freemantle N.
    Diabetes Obes Metab; 2025 Jan 12; 27(1):228-237. PubMed ID: 39420531
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
    Amin NB, Frederich R, Tsamandouras N, Haggag AZ, Schuster T, Zmuda W, Palmer A, Vasas S, Buckley G, Smith TR, DuBrava SJ, Zhu Q, Johnson M.
    Diabetes Obes Metab; 2025 Jan 12; 27(1):215-227. PubMed ID: 39415344
    [Abstract] [Full Text] [Related]

  • 9. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.
    Lankisch MR, Del Prato S, Dain MP, Mullins P, Owens DR.
    Prim Care Diabetes; 2016 Feb 12; 10(1):51-9. PubMed ID: 26150328
    [Abstract] [Full Text] [Related]

  • 10. REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.
    Cárdenas-Salas JJ, Sierra Poyatos RM, Luca BL, Sánchez Lechuga B, Modroño Móstoles N, Montoya Álvarez T, Gómez Montes MP, Ruiz Sánchez JG, Meneses González D, Sánchez-Lopez R, Casado Cases C, Pérez de Arenaza Pozo V, Vázquez Martínez C.
    J Diabetes Complications; 2024 Dec 12; 38(12):108874. PubMed ID: 39442257
    [Abstract] [Full Text] [Related]

  • 11. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR, DeYoung MB, Han J, Best JH, Grimm M.
    Cardiovasc Diabetol; 2013 Mar 23; 12():48. PubMed ID: 23522121
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of different basal insulin in type 2 diabetes mellitus with chronic kidney disease in Ramadan: prospective observational study.
    Baharum NH, Wan Muhammad Hatta SF, Zainordin NA, Abdul Ghani R.
    BMC Endocr Disord; 2024 Dec 02; 24(1):260. PubMed ID: 39617888
    [Abstract] [Full Text] [Related]

  • 13. Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes.
    Morales J, King A, Oser S, D'Souza S.
    Postgrad Med; 2024 Nov 02; 136(8):791-800. PubMed ID: 39348567
    [Abstract] [Full Text] [Related]

  • 14. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W, Traylor L, Wei W, Shi R, Ameer B, Vlajnic A, Nicolucci A.
    Diabetes Obes Metab; 2014 Mar 02; 16(3):255-61. PubMed ID: 24028669
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
    Dai M, Dai S, Gu L, Xiang Z, Xu A, Lu S, Yang Y, Zhou C.
    J Clin Res Pediatr Endocrinol; 2024 Sep 05; 16(3):323-333. PubMed ID: 38828884
    [Abstract] [Full Text] [Related]

  • 16. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A.
    Curr Med Res Opin; 2010 Jul 05; 26(7):1621-8. PubMed ID: 20429817
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T.
    Clin Ther; 2012 Sep 05; 34(9):1892-908.e1. PubMed ID: 22884767
    [Abstract] [Full Text] [Related]

  • 18. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
    Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS.
    J Hepatol; 2025 Jan 05; 82(1):7-17. PubMed ID: 39002641
    [Abstract] [Full Text] [Related]

  • 19. Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.
    Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M, Freeman K, Brown A, Court R, Baldwin S, Ogunlayi F, Stinton C, Cummins E, Al-Khudairy L.
    Health Technol Assess; 2024 Dec 05; 28(80):1-190. PubMed ID: 39673446
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes.
    Pandya N, DiGenio A, Gao L, Patel M.
    Drugs Aging; 2013 Jun 05; 30(6):429-38. PubMed ID: 23539233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.